Literature DB >> 22876742

Role of melatonin in mood disorders and the antidepressant effects of agomelatine.

Venkataramanujam Srinivasan1, Domenico De Berardis, Samuel D Shillcutt, Amnon Brzezinski.   

Abstract

INTRODUCTION: Disturbances of circadian rhythms and sleep play an important role in various types of mood disorders like major depressive disorder (MDD), bipolar depressive disorder (BPD) and seasonal affective disorder (SAD). Malfunctioning of the SCN-pineal-melatonin link has been suggested as the main cause for these disorders. As a rhythm-regulating factor and as a hormone involved in the regulation of sleep, melatonin is essential for the control of mood and behavior. AREAS COVERED: Melatonin's involvement in various mood disorders is reviewed based on studies undertaken in patients with MDD, BPD and SAD. The chemistry and metabolism of the newly introduced antidepressant, agomelatine, a MT1/MT2 melatonin receptor agonist and 5-HT2c antagonist in brain areas involved in mood regulation are also discussed. Its clinical role in mood regulation, agomelatine's efficacy, safety and tolerability are also reviewed. EXPERT OPINION: Agomelatine, a melatonergic antidepressant with a rapid onset of action, has been shown effective in various types of mood disorders (e.g., MDD, BPD, SAD). Some studies find it superior to other common antidepressants (SSRIs, SNRIs) that are in clinical use today. Agomelatine's efficacy, good tolerability and safety profile suggest that it may become a preferred antidepressant in the near future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22876742     DOI: 10.1517/13543784.2012.711314

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  15 in total

1.  Sleep Disorders in Postmenopausal Women.

Authors:  Shazia Jehan; Alina Masters-Isarilov; Idoko Salifu; Ferdinand Zizi; Girardin Jean-Louis; Seithikurippu R Pandi-Perumal; Ravi Gupta; Amnon Brzezinski; Samy I McFarlane
Journal:  J Sleep Disord Ther       Date:  2015-08-25

2.  Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature.

Authors:  Vesile Altınyazar; Nefati Kiylioglu
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-16

Review 3.  Rhythms of life: circadian disruption and brain disorders across the lifespan.

Authors:  Ryan W Logan; Colleen A McClung
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

4.  Sleep, Melatonin, and the Menopausal Transition: What Are the Links?

Authors:  Shazia Jehan; Giardin Jean-Louis; Ferdinand Zizi; Evan Auguste; Seitikurippu R Pandi-Perumal; Ravi Gupta; Hrayr Attarian; Samy I McFarlane; Rüdiger Hardeland; Amnon Brzezinski
Journal:  Sleep Sci       Date:  2017 Jan-Mar

5.  Melatonin and agomelatine for preventing seasonal affective disorder.

Authors:  Barbara Nussbaumer-Streit; Amy Greenblatt; Angela Kaminski-Hartenthaler; Megan G Van Noord; Catherine A Forneris; Laura C Morgan; Bradley N Gaynes; Jörg Wipplinger; Linda J Lux; Dietmar Winkler; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

6.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

7.  Psychological therapies for preventing seasonal affective disorder.

Authors:  Catherine A Forneris; Barbara Nussbaumer-Streit; Laura C Morgan; Amy Greenblatt; Megan G Van Noord; Bradley N Gaynes; Jörg Wipplinger; Linda J Lux; Dietmar Winkler; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2019-05-24

8.  GIRK Channels Mediate the Nonphotic Effects of Exogenous Melatonin.

Authors:  Lauren M Hablitz; Hylton E Molzof; Kathryn E Abrahamsson; Joanna M Cooper; Rebecca A Prosser; Karen L Gamble
Journal:  J Neurosci       Date:  2015-11-11       Impact factor: 6.167

9.  Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?

Authors:  Michele Fornaro; Fabio Bandini; Luca Cestari; Christian Cordano; Carla Ogliastro; Claudio Albano; Domenico De Berardis; Matteo Martino; Andrea Escelsior; Giulio Rocchi; Pantaleo Fornaro; Concetta De Pasquale
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-20       Impact factor: 2.570

Review 10.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.